Northwest Biotherapeutics, Inc.
NWBO · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.24 | 0.11 | -0.06 |
| FCF Yield | -3.77% | -2.07% | -3.03% | -6.04% |
| EV / EBITDA | -30.09 | -30.98 | -21.78 | -15.88 |
| Quality | ||||
| ROIC | 86.78% | 121.86% | 155.49% | 273.61% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.52 | 0.43 | 0.49 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | -23.39% | -16.57% | -11.98% | -6.36% |
| Free Cash Flow Growth | -93.02% | 25.76% | 53.51% | -140.92% |
| Safety | ||||
| Net Debt / EBITDA | -5.06 | -5.02 | -3.83 | -2.59 |
| Interest Coverage | 5.46 | -8.09 | -10.81 | -7.44 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -4,937.29 | 0.00 | 0.00 |